THERAPY DOSSIER · th-c22413aaa90c

CX3CL1 (fractalkine)

Biologic · Biologic (CX3CL1/fractalkine chemokine); no confident ChEMBL drug match, preclinical

Evidence & regulatory context

Mechanism: Biologic (CX3CL1/fractalkine chemokine); no confident ChEMBL drug match, preclinical
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22072684 ↗2011Mixed findings

CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents.

MixedIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6 wild type, cx3cl1 knockout, cx3cr1(GFP/GFP) and adenosine A1 receptor knockout miceMaleAcute administration at the time of permanent middle cerebral artery occlusion

Model: Permanent middle cerebral artery occlusion, with in vitro oxygen-glucose deprivation

Exogenous CX3CL1 reduced infarct size, neurological deficits and caspase-3 activation with effects lasting up to 50 days, dependent on adenosine A1 receptor signalling, yet cx3cl1 and cx3cr1 deficient mice sustained less injury and CX3CL1 increased damage in cx3cl1 knockout mice.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…